For US Residents
PLUVICTO LogoPLUVICTO Logo
Phone IconPhone-icon
Call Us
Get access to the support you need in just 2-3 minutes.
Novartis Patient Supportoffers:
Icon of a support person wearing a headset
1:1 Patient Navigation Support

Dedicated team supporting patients and care partners. Providing guidance with the referral process, financial assistance, treatment information and answers to common questions. Once enrolled you will receive:

  • A welcome kit in the mail with information about PLUVICTO
  • A call from our Novartis Patient Navigator within 2 business days to answer your questions and support your needs
If you’d like to sign up on the phone, call 1-844-638-7222, Monday-Friday, 8:00 AM-8:00 PM ET (excluding holidays).
8/26 FA-11767513

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts, which may be severe and life-threatening. Tell your doctor right away if you develop any new or worsening symptoms, including:

  • Tiredness or weakness
  • Pale skin
  • Shortness of breath
  • Bleeding or bruising more easily than normal or difficulty stopping bleeding
  • Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Kidney problems, which can be severe. You should stay well hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby.

  • You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent infertility.

The most common side effects of PLUVICTO include:
  • Decreased blood cell counts
  • Laboratory abnormalities
  • Tiredness
  • Dry mouth
  • Nausea
  • Kidney problems

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information.

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with metastatic prostate-specific membrane antigen–positive (PSMA+) prostate cancer and are:

  • androgen pathway modulation-naïve or -sensitive (mAPMN/S) in combination with hormone therapy, or
  • androgen pathway modulation-resistant (mAPMR) after hormone therapy, and
  • appropriate to delay chemotherapy, or
  • have received prior chemotherapy
8/26 FA-11767513